Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx (AMLX) to $18 from $16 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q3 report.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $20 from $16 at H.C. Wainwright
- Amylyx Pharmaceuticals Reports Strong Q3 2025 Results
- Amylyx Pharmaceuticals: Positive Earnings Call Highlights Progress and Challenges
- Buy Rating for Amylyx Pharmaceuticals: Strong Financial Health and Promising Pipeline Developments
- Buy Rating for Amylyx Pharmaceuticals: Promising Phase III Study and Market Potential for Avexitide